AffiliationCell Signaling Group, Cancer Research UK Manchester Institute, The University of Manchester , Manchester , UK
MetadataShow full item record
AbstractIn vitro and in vivo studies and evidence from human tumors have long implicated Rho GTPase signaling in the formation and dissemination of a range of cancers. Recently next generation sequencing has identified direct mutations of Rho GTPases in human cancers. Moreover, the effects of ablating genes encoding Rho GTPases and their regulators in mouse models, or through pharmacological inhibition, strongly suggests that targeting Rho GTPase signaling could constitute an effective treatment. In this review we will explore the various ways in which Rho signaling can be deregulated in human cancers.
CitationDeregulation of Rho GTPases in cancer. 2016:1-16 Small GTPases
- Approaches of targeting Rho GTPases in cancer drug discovery.
- Authors: Lin Y, Zheng Y
- Issue date: 2015
- Rho GTPases as therapeutic targets in cancer (Review).
- Authors: Cardama GA, Gonzalez N, Maggio J, Menna PL, Gomez DE
- Issue date: 2017 Oct
- Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors.
- Authors: Olson MF
- Issue date: 2018 May 4
- Mutationally activated Rho GTPases in cancer.
- Authors: Alan JK, Lundquist EA
- Issue date: 2013 Jul-Sep
- Rho GTPase expression in tumourigenesis: evidence for a significant link.
- Authors: Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C, Lacal JC
- Issue date: 2005 Jun